CTOs on the Move

Dent Neurologic Institute

www.dentinstitute.com

 
The DENT Neurologic Institute is among the largest, most comprehensive neurology practices in the United States. We are focused on providing superior clinical care, advanced diagnostic services, clinical research, and education.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

BioCareSD

BioCareSD is a specialty distributor of biological products for hemophilia, thrombophilia, immunology, critical care, and ALS. They are committed to providing customer-oriented solutions, unmatched service levels, and a unique distribution network to e...

ERT

ERT is a global company specializing in clinical services and customizable medical devices to biopharmaceutical and healthcare organizations.

KV Pharmaceutical Company

KV Pharmaceutical Company is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Turbaremanufacturing

Turbare Manufacturing is a company that specializes in the sterile production of intravenous medications, FDA drug shortage preparations, and critical medication preparations to help fulfill the critical needs in the pharmaceutical supply chain.

Eupraxia Pharmaceuticals

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia`s product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia`s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.